Skip to main content

Peer Review reports

From: A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification

Original Submission
22 Oct 2015 Submitted Original manuscript
6 Nov 2015 Author responded Author comments - Line Tarpgaard
Resubmission - Version 2
6 Nov 2015 Submitted Manuscript version 2
21 Jan 2016 Author responded Author comments - Line Tarpgaard
Resubmission - Version 3
21 Jan 2016 Submitted Manuscript version 3
Publishing
3 Feb 2016 Editorially accepted
11 Feb 2016 Article published 10.1186/s12885-016-2124-5

You can find further information about peer review here.

Back to article page